As of May 27, 2025, Pluristem Therapeutics Inc (PSTI) reports a Forward P/E of N/A.
Forward P/E gauges the price investors pay for each dollar of anticipated earnings, offering insight into a stock's future valuation.
Comparing Pluristem Therapeutics Inc's Forward P/E to Peers
To better understand Pluristem Therapeutics Inc's position, it's useful to compare its Forward P/E against industry peers. Below are selected comparisons:
| Company | Forward P/E |
|---|---|
| Pluristem Therapeutics Inc (PSTI) | - |
| Fennec Pharmaceuticals Inc (FENC) | 75.95 |
| Kamada Ltd (KMDA) | 21.64 |
Compared to its competitors, Pluristem Therapeutics Inc's Forward P/E is difficult to compare due to insufficient data.